Are Wegovy and Ozempic the same drug?
Yes — and no. Both Wegovy and Ozempic contain semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. The active molecule is identical. What differs is the approved dose, the approved indication, the brand name, and the price.
Ozempic was approved first, in 2017, for Type 2 diabetes management. During clinical trials, the weight loss produced as a side effect was significant enough that Novo Nordisk developed a higher-dose version — Wegovy — specifically approved for chronic weight management in 2021.
Both are weekly subcutaneous injections. Both use a pen device. Both are semaglutide. The difference is primarily regulatory, dosing, and who can get them covered by insurance.
Key differences between Wegovy and Ozempic
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval | Type 2 diabetes | Chronic weight management |
| Max approved dose | 2 mg weekly | 2.4 mg weekly |
| Typical weight loss | 10–15% | 15–20% |
| Insurance coverage | Yes (with T2D diagnosis) | Limited — varies by plan |
| Monthly cost (without insurance) | ~$900–1,000 | ~$1,300–1,400 |
| Off-label for weight loss? | Yes — commonly prescribed | Approved indication |
Which is better for weight loss?
Wegovy produces more weight loss on average — because it's approved at a higher dose (2.4mg vs 2mg). The STEP trials for Wegovy showed average weight loss of 15–20% of body weight over 68 weeks. Ozempic's weight loss trials showed 10–15%.
However, both produce significant weight loss compared to placebo. For people who can't access Wegovy due to cost or availability, Ozempic at its maximum dose produces meaningful results. Many prescribers prescribe Ozempic off-label for weight management when Wegovy is unavailable or not covered.
Insurance matters a lot here. Wegovy is approved for weight loss and more insurance plans are covering it — but coverage is still inconsistent. Ozempic is more reliably covered for people with a Type 2 diabetes diagnosis. Without insurance, both are expensive ($900–1,400/month).
Which is better for Type 2 diabetes?
For Type 2 diabetes management, Ozempic is the appropriate choice — it's the approved medication for this indication and is more reliably covered by insurance including Medicare for people with a T2D diagnosis.
Wegovy can be used in people with both Type 2 diabetes and obesity, but the additional blood sugar benefits of the higher dose versus Ozempic's maximum dose are modest. Most endocrinologists prescribe Ozempic for blood sugar management and Wegovy specifically when weight loss is the primary goal.
Using CGM to track Wegovy vs Ozempic results
Whether you're on Wegovy or Ozempic, CGM gives you the most direct real-time view of how the medication is affecting your metabolism. You'll see post-meal glucose peaks flatten, fasting glucose drop, and overall glucose variability reduce — changes that a quarterly HbA1c captures only in aggregate.
CGM is particularly useful during dose titration — when your prescriber is adjusting your dose every 4 weeks, CGM shows the glucose effect of each change immediately rather than waiting months for the next lab test.
For most Wegovy/Ozempic users not on insulin: Dexcom Stelo ($89–99/month, no prescription) is the top OTC recommendation. See our full GLP-1 CGM guide →